While AAV capsid selection dictates viral tropism, the gene expression cassette determines the ultimate strength, specificity, and safety of target gene expression within host cells. Conventional wild-type promoters and standard regulatory elements often suffer from non-specific leakage, expression waning, or high dosage requirements—which can trigger host immune responses and dose-dependent toxicity.
To solve these translational obstacles, Protheragen presents the intelligent gene expression cassette optimization platform. By integrating AI-driven regulatory element modeling, systematic multi-element combinatorial screening, and synthetic biology engineering, we fine-tune every regulatory module within the AAV vector. Our platform enables robust, tissue-restricted expression at significantly reduced vector genome (VG) doses, elevating both therapeutic index and clinical safety.
Our platform optimizes the full transcriptional and post-transcriptional architecture of the AAV cassette by combining compact synthetic promoters with rational modular engineering. Ultra-short, tissue-specific promoters and optimized introns drive robust, targeted gene expression while maximizing available payload space.
To maximize safety and durability, we integrate 3' UTR microRNA target sites for off-target organ detargeting alongside systematic CpG depletion and codon optimization. This dual approach evades host immune recognition and achieves therapeutic expression levels at significantly lower vector doses.
Fig.1 AAV expression cassette components and their modifications. (Kolesnik VV, et al., 2024)
Protheragen provides a comprehensive, 6-point modular service portfolio to build highly tailored AAV expression cassettes:
In silico prediction and high-throughput cell-based/in vivo screening of compact synthetic promoters tailored for specific tissue or cell types.
Custom combination of enhancers, synthetic promoters, minimal introns, and optimized polyA sequences to achieve high expression within strict payload size limits.
Integration of cell-type specific microRNA (miRNA) target sites into the 3' UTR to suppress transgene expression in non-target organs (e.g., liver, DRG).
Algorithms designed to optimize mRNA stability, remove cryptic splice sites, and deplete CpG motifs for reduced host immunogenicity.
RT-qPCR, Western blotting, and spatial transcriptomics to quantify promoter strength, tissue specificity, and dynamic regulation.
Comparative in vivo efficacy studies across optimized vs. wild-type cassettes to establish minimum effective dosage (MED) and safety margins across 20+ disease models.
Our intelligent gene expression cassette optimization platform provides tailored solutions across multiple therapeutic areas:
At Protheragen, we bring together cutting-edge synthetic biology, AI-guided element design, and extensive preclinical packaging experience to engineer state-of-the-art AAV expression cassettes. Our platform goes beyond standard plasmid construction, offering fully integrated design, high-throughput screening, and animal model validation. Partner with Protheragen to optimize your gene expression cassette, lower your clinical dosage requirements, and build safer, more potent AAV candidates.
Contact our expression cassette engineering experts today to discuss your target tissue, request promoter design options, or get a custom proposal.
Reference
Our AAVLinkTM platform is at the forefront of adeno-associated viral (AAV) vector development, leveraging our extensive expertise and state-of-the-art technologies to drive innovation in gene therapy.
